Experience

Davis Polk advised the remarketing agents on the remarketing of 750,000 shares of Stanley Black & Decker’s Series C cumulative perpetual convertible preferred stock, without par…

Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $1.05 billion aggregate principal amount of its 0.250%…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Callaway Golf Company of $258.75 million aggregate principal amount of its 2.75% convertible senior…

Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by NeoGenomics, Inc. of 4,400,000 shares of its common stock and $175 million…

Davis Polk advised ADC Therapeutics SA in connection with its entry into a facility agreement with Deerfield Partners, L.P., pursuant to which Deerfield agreed to extend senior secured…

Davis Polk advised the forward purchasers and forward sellers in connection with an at-the-market forward underwriting program for the offer and sale of shares of common stock of CMS Energy…

Davis Polk advised Morgan Stanley in connection with its SEC-registered global offering of $3 billion aggregate principal amount of fixed-to-floating-rate senior notes due 2026. During the…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Inphi Corporation of $506 million aggregate principal amount of its 0.75%…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Cree, Inc. of $575 million aggregate principal amount of its 1.750% convertible…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Coherus BioSciences, Inc. of $200 million aggregate principal amount of its…